TNFRSF17 and plasma cell myeloma: CAR T has dramatically changed the management of B-cell malignancies by targeting antigens, such as CD19 for B-cell lymphomas [61,62,63] and B-cell maturation antigen (BCMA) for multiple myeloma [64].